Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Sets Up U.S. Vaccine Center
by Ann M. Thayer
April 13, 2015
| A version of this story appeared in
Volume 93, Issue 15
GlaxoSmithKline will create a new global center for vaccines R&D in Rockville, Md. The firm will consolidate vaccines R&D under way in Cambridge, Mass., and Philadelphia at the Maryland site. Starting up as early as September, the new site will house about 1,000 people by 2016, including about 400 already working there in manufacturing. GSK employs about 150 people at both the Cambridge and Philadelphia sites. Besides the Rockville site, which GSK acquired in 2012, the firm has vaccine R&D centers in Rixensart, Belgium, and Siena, Italy. GSK added the Siena site when it acquired Novartis’s vaccines business last month.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X